BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

NextGen Sciences Ltd. Launches Multiple Protein Plasma Oncology Biomarker Assay


3/16/2011 10:54:47 AM

Ann Arbor, Michigan, US, and London, UK, 16 March 2011 – NextGen Group plc (AIM:NGG) is pleased to announce that its subsidiary NextGen Sciences Inc, a leader in biomarker discovery, measurement and qualification, has launched its first multiple protein (multiplex) assay, plasmadiscovery41, for oncology biomarker discovery and qualification. The assay simultaneously measures 41 human plasma proteins that are thought to have potential as biomarkers in cancer, particularly breast, prostate and lung cancers. The launch of plasmadiscovery41 is part of NextGen Sciences strategy of becoming a leading player in the growing oncology and central nervous system (CNS) biomarker markets.

NextGen’s assay is based upon its multiple reaction monitoring (MRM) mass spectrometry platform, and generates high quality reproducible data that companies can use in their drug and diagnostic development programmes. In addition to the cancer focus, the assay can be used for early-stage biomarker discovery and qualification in other disease areas. NextGen expects to continue to add proteins to the plasmadiscovery41 assay, in addition to developing other disease-focused assay panels, both as proprietary products and with other companies through partnerships and collaborations.

Klaus Rosenau, Chairman and CEO of NextGen Group, commented, ‘The release of plasmadiscovery41 is a defining first step in the development of NextGen Sciences’ biomarker business, following its recent reorganization. It demonstrates that we are now delivering on our plans to develop multiplex protein assays and will help to establish the company as a market leader in biomarker discovery and qualification using its MRM technology. Importantly, it enables us to aggressively target increasing market share from the $600m mass spectrometry based biomarker discovery market. We believe that pharmaceutical, biotechnology and diagnostics companies need high-quality assays relevant to their disease areas to inform their decision-making processes, and NextGen Sciences expects to launch more such products in the future.’.

For more information please contact :

NextGen Group Klaus Rosenau, Chairman and CEO klaus.rosenau@nextgensciences.com +49 160 551 6756

Seymour Pierce Jonathan Wright, Nicola Marrin +44 (0) 20 7107 8000

NextGen Sciences Inc (Ann Arbor, MI, USA) is the subsidiary of NextGen Group PLC, London, UK (AIM: NGG). It provides pharmaceutical, biotechnology and diagnostic companies with rapid and quantitative protein biomarker discovery, measurement and qualification services using mass spectrometry technology. With a rise in the industry focus on personalized medicine and cost-effectiveness, biomarkers are playing an increasing important role in drug discovery, development and patient access, as well as healthcare delivery. The global market for biomarkers is expected to grow to $12.8bn by 2012 (BCC Research), with those for neurological disorders ($3.5bn by 2015, Espicom Healthcare) and oncology ($9.5bn by 2014, www.marketsandmarkets.com) playing an important role. NextGen Sciences’ products include discoveryexpress for discovery of new biomarkers and targets, assayexpress for assay development and testingexpress for biomarker qualification. For more information visit www.nextgensciences.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES